Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

LVTX | LAVA Therapeutics NV

Index- P/E- EPS (ttm)-1.55 Insider Own55.42% Shs Outstand26.29M Perf Week-3.29%
Market Cap38.65M Forward P/E- EPS next Y-1.67 Insider Trans0.00% Shs Float11.72M Perf Month-18.78%
Income-40.64M PEG- EPS next Q-0.49 Inst Own12.73% Short Float / Ratio0.32% / 1.15 Perf Quarter-27.59%
Sales24.26M P/S1.59 EPS this Y-42.48% Inst Trans-2.66% Short Interest0.04M Perf Half Y-11.98%
Book/sh2.86 P/B0.51 EPS next Y4.85% ROA- Target Price6.80 Perf Year-69.05%
Cash/sh4.28 P/C0.34 EPS next 5Y- ROE- 52W Range1.37 - 7.38 Perf YTD-58.00%
Dividend- P/FCF- EPS past 5Y- ROI-62.32% 52W High-80.08% Beta-0.30
Dividend %- Quick Ratio5.54 Sales past 5Y103.25% Gross Margin- 52W Low7.69% ATR0.08
Employees69 Current Ratio5.31 Sales Q/Q413.90% Oper. Margin-165.49% RSI (14)32.61 Volatility3.24% 4.51%
OptionableYes Debt/Eq0.11 EPS Q/Q-17.97% Profit Margin-167.49% Rel Volume0.15 Prev Close1.49
ShortableYes LT Debt/Eq0.02 EarningsAug 22 BMO Payout- Avg Volume32.81K Price1.47
Recom1.00 SMA20-10.99% SMA50-16.04% SMA200-35.00% Volume4,831 Change-1.34%
Date Action Analyst Rating Change Price Target Change
Oct-25-22Initiated H.C. Wainwright Buy $9
Apr-19-21Initiated SVB Leerink Outperform $26
Apr-19-21Initiated JP Morgan Overweight $22
Apr-19-21Initiated Jefferies Buy $23
Sep-06-23 07:11AM
Aug-22-23 07:00AM
Aug-14-23 07:00AM
Jun-14-23 09:00AM
Jun-08-23 07:00AM
04:20PM Loading…
Jun-01-23 04:20PM
May-30-23 05:28PM
Apr-11-23 07:00AM
Mar-09-23 08:05AM
Feb-16-23 07:00AM
Feb-09-23 07:00AM
Feb-06-23 07:00AM
Jan-23-23 07:00AM
Jan-06-23 01:07PM
07:00AM Loading…
Jan-03-23 07:00AM
Dec-10-22 10:00AM
Nov-16-22 04:05PM
Nov-03-22 04:05PM
Nov-01-22 07:00AM
Oct-07-22 11:00AM
Sep-26-22 08:00AM
Sep-13-22 04:05PM
Sep-07-22 07:41AM
Jun-16-22 04:05PM
Jun-15-22 07:00AM
Jun-02-22 07:00AM
Jun-01-22 07:00AM
May-31-22 04:05PM
07:00AM Loading…
May-17-22 07:00AM
May-12-22 07:00AM
May-05-22 03:44PM
Apr-27-22 10:05AM
Mar-24-22 06:30AM
Mar-22-22 05:20PM
Mar-10-22 06:30AM
Mar-07-22 08:35AM
Feb-01-22 06:30AM
Jan-28-22 07:00AM
Jan-18-22 08:30AM
Dec-20-21 10:06AM
Nov-15-21 07:00AM
Nov-11-21 12:16PM
Nov-09-21 06:30AM
Nov-04-21 07:00AM
Nov-02-21 07:00AM
Oct-15-21 07:00AM
Oct-07-21 12:36PM
Sep-23-21 10:26AM
Aug-16-21 07:05AM
Jul-27-21 08:00AM
Jul-13-21 07:00AM
May-25-21 06:30AM
May-20-21 06:30AM
May-18-21 06:30AM
May-10-21 09:29AM
Apr-01-21 07:54AM
Mar-25-21 11:31AM
Mar-24-21 08:55PM
LAVA Therapeutics NV is an immuno-oncology company. It utilizes its proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.